loader
Page is loading...
OVERVIEW

Jim F. Murdica
Partner

Los Angeles

2029 Century Park East
Suite 300
Los Angeles, CA 90067

Chicago

One N. Wacker Drive
Suite 4400
Chicago, IL 60606-2833

New York

445 Park Avenue
Suite 700
New York, NY 10022-8634

P 312-214-4869

F 310-284-3894

OVERVIEW

Jim F. Murdica
Partner

Los Angeles

2029 Century Park East
Suite 300
Los Angeles, CA 90067

Chicago

One N. Wacker Drive
Suite 4400
Chicago, IL 60606-2833

New York

445 Park Avenue
Suite 700
New York, NY 10022-8634

P 312-214-4869

F 310-284-3894

Jim Murdica is chairman of the Product Liability and Mass Torts practice. Since 2016, Jim has been recognized by Chambers USA for his work in product liability and mass tort in the nationwide category.

Jim Murdica is chairman of the Product Liability and Mass Torts practice. Since 2016, Jim has been recognized by Chambers USA for his work in product liability and mass tort in the nationwide category.

OVERVIEW

Jim Murdica is chairman of the Product Liability and Mass Torts practice. Since 2016, Jim has been recognized by Chambers USA for his work in product liability and mass tort in the nationwide category.

Jim's practice focuses on the defense of pharmaceutical, medical device and consumer product litigation in state and federal courts nationwide, particularly consolidated mass torts and multi-district litigations.

In Chambers, clients describe Jim as having "[a]n incredible ability to synthesize complex scientific issues into very persuasive arguments that can be used both in court and in negotiations with the other side."

He serves as national coordinating counsel and MDL counsel for consolidated litigations across the U.S. involving thousands of plaintiffs as well as in numerous single-plaintiff cases involving pharmaceuticals, consumer products and medical devices. In conjunction with those roles, Jim emphasizes efficient discovery and manages significant mass tort e-discovery undertakings for his clients.

Jim has also coordinated the resolution of some of the largest, mass torts of the last decade.

Jim also counsels clients on product liability due diligence related to potential acquisitions and divestitures.

Regarding pharmaceutical and biologic manufacturers, Jim's experience includes:

  • Coordinating the national defense of a prescription diabetes drug alleged to have caused a multitude of injuries
  • Coordinating the national defense and acting as MDL counsel for the defense of several thousand litigations and claims alleging serious nervous system and vascular injuries from the use of a prescription antibiotic
  • Coordinating the national defense of hundreds of consolidated litigations alleging birth defects from exposure to an anticonvulsant medication in the Philadelphia Mass Torts Division
  • Coordinating the defense of consolidated state litigations in California alleging a life-threatening skin condition and tendon injuries from the use of a prescription antibiotic
  • Defending or assisting in the defense of consolidated and single plaintiff litigations regarding: anticoagulant medication, antidiabetic mediation, antipsychotic medications, antiepileptic medication, antibiotic medications, and various biologics that inhibit factors and bind proteins

Regarding medical device and consumer products manufacturers, Jim's experience includes:

  • Coordinating the national defense and serving as MDL counsel in the defense of a laparoscopic gynecologic surgical instrument for a medical device manufacturer
  • Coordinating the national defense of more than a thousand litigants and serving as lead counsel in a consolidated state proceeding regarding vena cava filters for a medical device manufacturer
  • Coordinating the national defense of contact lenses and vision devices for multiple medical device manufacturers
  • Coordinating the national defense of personal injury litigations for a cardiac catheter manufacturer
  • Defending the manufacturer of cardiac stents in a nationwide litigation alleging personal injuries from use of the device
  • Acting as national counsel for a manufacturer of skincare products

Jim is not regularly admitted to practice in the local courts of Illinois.

EXPERIENCE
Publications and Presentations
  • "Emerging Issue in Mass Torts," UT Colloquium on Complex Litigation, University of Texas School of Law, 2019 (Guest lecturer)
  • “Critical Complex Litigation Components,” 19th Annual Complex Litigation Symposium, 2019
  • “Complex Litigation: Ethical Conundrums,” Harris Martin MDL Conference, 2019
  • “New Drug Application Conflict Preemption Defense Gains Traction in Utts v. Bristol-Myers Squibb Co.,” Natl. Law Review, Feb. 2017
  • 'New Drug Application Conflict Preemption Defense Gains Traction in Utts' BT Product Liability Blog, Feb. 10, 2017 (Author) *republished in The National Law Review
  • 'Tools for the 'New World' of eDiscovery and Information Governance' Barnes & Thornburg CLE, Dec. 14, 2016 (Speaker)
  • "A Practical Guide to Using Tools in the Defense Arsenal to Fight Litigation Tourism and Frivolous Litigation" ACI Annual Drug & Medical Device Litigation conference, Dec. 6, 2016 (Speaker)
  • “A Practical Guide to Using Tools in the Defense Arsenal to Fight Litigation Tourism and Frivolous Litigation,” American Conference Institute Drug & Medical Device Conference, 2016
  • 'Preserving the Medical Device Preemption Defense in Light of Contrary Court Decisions and a Resurgence of Off-Label Attacks' ACI Annual Drug & Medical Device Litigation conference, Dec. 3, 2015 (Panelist)
  • 'How to Streamline eDiscovery' The Masters Conference, July 16, 2015 (Panelist)
  • “Preserving the Medical Device Preemption Defense in Light of Contrary Court Decisions and a Resurgence of Off-Label Attacks,” American Conference Institute Drug & Medical Device Conference, 2015
  • 'Off-Label Treatment: Use of Cancer Drugs Outside of Conventional Trials and Government Approvals' JALBCA Symposium, Nov. 20, 2014 (Panelist)
  • “The Biomaterials Access Assurance Act: An Underused Tool Against Forum Shopping,” For the Defense, Sept. 2014 (Co-author)
  • “Off-Label Treatment: Use of Cancer Drugs Outside of Conventional Trials and Government Approvals,” JALBCA Nineteenth Annual Ellen P. Hermanson Memorial Symposium, 2014
  • 'The Biomaterials Access Assurance Act: An Underused Tool Against Forum Shopping' DRI For The Defense, Sept. 2014 (Co-Author)
  • 'Product Liability ' Case Law Update 2014' DRI Case Law Update, 2014 (Author)
  • “Formulating your Device Defense from Day One: Evolving Regulations and Online Resources,” Defense Research Institute Drug & Medical Device Conference, 2013
  • 'Formulating Your Device Defense from Day One: Evolving Regulations and Online Resources' DRI Drug and Medical Device Seminar, May 17, 2013 (Speaker)
  • 'Product Liability ' Case Law Update 2010' DRI Case Law Update, 2010 (Author)
INSIGHTS & EVENTS
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.